A Multicenter, Post-Market Clinical Follow-up Study of Subjects With the REDAPT™ System Monolithic Sleeveless/Sleeved Stem and/or Fully Porous Acetabular Shell With XLPE Liner and/or Modular Shell Components Previously Implanted

Retrospective-prospective, single arm, multicenter study of subjects previously implanted with the REDAPT System Monolithic Sleeveless/Sleeved Stem and/or Fully Porous Acetabular Shell with XLPE liner and/or Modular Shell Components (with or without Staple, Slice and Blade Augments).

Inclusion criteria

Subjects must meet all of the inclusion criteria to enroll in the study:

• Subject was considered skeletally mature at the time of surgery and was at least 18 years of age.
• Subject has undergone hip arthroplasty with the REDAPT Fully Porous Acetabular Shell with XLPE liner or REDAPT Modular Cup Components (with or without Staple, Slice and Blade Augments), and/or Monolithic Sleeveless Stem, and/or Monolithic Sleeved Stem and are at least 3 months post-implantation at this site.
• Subject required surgery with REDAPT device chosen for one of the following indications:

• Advanced degeneration of the hip joint as result of osteoarthritis, avascular necrosis, posttraumatic arthritis, rheumatoid arthritis, or dysplasia (or any of the composites of these conditions).
• Fracture-dislocation of the hip, femoral neck fracture or trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques.
• Revision THA
• Subject is willing to consent to and to follow the study visit schedule (as defined in the study protocol and ICF), by signing the IRB/IEC approved ICF.
• Subject is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures.

Exclusion criteria

Subjects meeting any of the following exclusion criteria will be excluded from study participation:

• Subject had an active infection - systemic or at the site of surgery.
• Subject, in the opinion of the PI, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
• Subject is known to be at risk for loss to follow-up or failure to return for scheduled visits.
• Subject is incarcerated or is pending incarceration.
• Subject is enrolled in another clinical study that would affect the endpoints of the study.